Abiopharma

INTELLIA THERAPEUTICS, INC. (NTLA)

Symbol	NTLA
Name	INTELLIA THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: In Vitro & In Vivo Diagnostic Substances
Address	40 ERIE STREET,SUITE 130, CAMBRIDGE, Massachusetts, 02139, United States
Telephone	+1 -857 285-6200
Fax	—
Email	—
Website	https://www.intelliatx.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001652130
Description	Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. Its evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. Additional info from NASDAQ: Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. Its evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

2026-08-20 20:03

📋 LEONARD JOHN M (Officer) plans to sell 23K shares of Intellia Therapeutics, Inc. (at $12.95 each, total $294K) Filed: Aug 20, 2026 | ID: 000938

2026-08-07 20:01

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-07 10:55

New Form SCHEDULE 13G - Intellia Therapeutics, Inc. Filed: 2026-08-07 AccNo: 0000093751-26-000484 Size: 8 KB

2026-08-06 11:00

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

2026-07-30 12:00

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

2026-07-24 21:26

Dulac Edward J III 🔴 sold 8.1K shares of Intellia Therapeutics, Inc. (NTLA) at $11.25 Transaction Date: Jul 22, 2026 | Filing ID: 316279

2026-07-06 21:02

Dube Michael P 🔴 sold 2.6K shares of Intellia Therapeutics, Inc. (NTLA) at $16.78 Transaction Date: Jul 01, 2026 | Filing ID: 000002

2026-07-06 21:01

Dulac Edward J III 🔴 sold 4.7K shares of Intellia Therapeutics, Inc. (NTLA) at $18.00 Transaction Date: Jul 02, 2026 | Filing ID: 000002

2026-07-06 20:05

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-07-02 20:32

📋 EDWARD DULAC (Officer) plans to sell 5K shares of INTELLIA THERAPEUTICS, INC. (at $17.24 each, total $81K) Filed: Jul 02, 2026 | ID: 006836

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT06634420	HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary An…	Phase3	Hereditary Angioedema	Active_Not_Recruiting	2025-01-15	2027-09-01	ClinicalTrials.gov
NCT06634420	HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary An…	Phase3	Hereditary Angioedema	Active_Not_Recruiting	2025-01-15	2027-09-01	ClinicalTrials.gov
NCT06622668	NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease	Phase1	Lung Disease	Withdrawn	2024-11-20	2025-01-09	ClinicalTrials.gov
NCT06622668	NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease	Phase1	Lung Disease	Withdrawn	2024-11-20	2025-01-09	ClinicalTrials.gov
NCT06262399	Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002	—	Hereditary Angioedema	Enrolling_By_Invitation	2024-04-12	2040-04-01	ClinicalTrials.gov
NCT06262399	Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002	—	Hereditary Angioedema	Enrolling_By_Invitation	2024-04-12	2040-04-01	ClinicalTrials.gov
NCT05697861	Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001	—	Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy	Enrolling_By_Invitation	2023-07-10	2038-03-01	ClinicalTrials.gov
NCT05697861	Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001	—	Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy	Enrolling_By_Invitation	2023-07-10	2038-03-01	ClinicalTrials.gov
NCT05066165	Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia	Phase1	Acute Myeloid Leukemia	Terminated	2021-12-17	2022-08-31	ClinicalTrials.gov
NCT05066165	Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia	Phase1	Acute Myeloid Leukemia	Terminated	2021-12-17	2022-08-31	ClinicalTrials.gov
NCT05120830	NTLA-2002 in Adults With Hereditary Angioedema (HAE)	Phase1	Hereditary Angioedema	Active_Not_Recruiting	2021-12-10	2026-07-01	ClinicalTrials.gov
NCT05120830	NTLA-2002 in Adults With Hereditary Angioedema (HAE)	Phase1	Hereditary Angioedema	Active_Not_Recruiting	2021-12-10	2026-07-01	ClinicalTrials.gov
NCT04601051	Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics …	Phase1	Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy	Completed	2020-11-05	2025-09-12	ClinicalTrials.gov
NCT04601051	Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics …	Phase1	Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy	Completed	2020-11-05	2025-09-12	ClinicalTrials.gov

Total clinical trials: 14

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Normal Saline IV Administration	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2002	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
Normal Saline IV Administration	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2002	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
Normal Saline IV Administration	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2002	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
Normal Saline IV Administration	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2002	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
Normal Saline IV Administration	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2002	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
Normal Saline IV Administration	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2002	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
Normal Saline IV Administration	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2002	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
Normal Saline IV Administration	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2002	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
Normal Saline IV Administration	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2002	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
Arm 2: NTLA-5001	Other	Phase PHASE1	Acute Myeloid Leukemia	TERMINATED	NCT05066165
Arm 1: NTLA-5001	Other	Phase PHASE1	Acute Myeloid Leukemia	TERMINATED	NCT05066165
Biological NTLA-3001	Other	Phase PHASE1	Lung Disease	WITHDRAWN	NCT06622668
Normal Saline IV Administration	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2002	Other	Phase PHASE3	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT06634420
NTLA-2001	Other	Phase PHASE1	Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy	COMPLETED	NCT04601051
Normal Saline IV Administration	Other	Phase PHASE1	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT05120830
Biological NTLA-2002	Other	Phase PHASE1	Hereditary Angioedema	ACTIVE_NOT_RECRUITING	NCT05120830

Total products: 26